Adicet Bio, Inc. Depreciation
Adicet Bio, Inc. (ACET) reported Depreciation of $1.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- Adicet Bio, Inc. depreciation for the quarter ending 2026-06-30 was $1.20M, a 27.55% decline year-over-year.
- Adicet Bio, Inc. depreciation for the quarter ending 2026-03-31 was $1.34M, a 20.12% decline year-over-year.
- Adicet Bio, Inc. depreciation for the quarter ending 2025-12-31 was $1.47M, a 9.19% decline year-over-year.
- Adicet Bio, Inc. depreciation for the quarter ending 2025-09-30 was $1.57M, a 1.26% decline year-over-year.
- Adicet Bio, Inc. depreciation for fiscal 2025 was $6.38M, a 1.35% decline from fiscal 2024.
- Adicet Bio, Inc. depreciation for fiscal 2024 was $6.47M, a 6.07% increase from fiscal 2023.
- Adicet Bio, Inc. depreciation for fiscal 2023 was $6.10M.
- Adicet Bio, Inc. depreciation for fiscal 2019 was $100.00K, a 25.00% increase from fiscal 2018.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.20M 10-Q · filed 2026-08-05 | $2.54M 10-Q · filed 2026-08-05 | $4.01M derived: sum of 3 quarters · filed 2026-08-05 | $5.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.34M 10-Q · filed 2026-05-13 | $2.81M derived: sum of 2 quarters · filed 2026-05-13 | $4.39M derived: sum of 3 quarters · filed 2026-05-13 | $6.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.05M derived: sum of 2 quarters · filed 2026-03-12 | $4.70M derived: sum of 3 quarters · filed 2026-08-05 | $6.38M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.57M 10-Q · filed 2025-11-05 | $3.23M derived: sum of 2 quarters · filed 2026-08-05 | $4.91M 10-Q · filed 2025-11-05 | $6.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.66M 10-Q · filed 2026-08-05 | $3.33M 10-Q · filed 2026-08-05 | $4.96M derived: sum of 3 quarters · filed 2026-08-05 | $6.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.68M 10-Q · filed 2026-05-13 | $3.30M derived: sum of 2 quarters · filed 2026-05-13 | $4.89M derived: sum of 3 quarters · filed 2026-05-13 | $6.50M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.21M derived: sum of 2 quarters · filed 2026-03-12 | $4.82M derived: sum of 3 quarters · filed 2026-03-12 | $6.47M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.59M 10-Q · filed 2025-11-05 | $3.19M derived: sum of 2 quarters · filed 2025-11-05 | $4.85M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $1.60M 10-Q · filed 2025-08-07 | $3.25M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $1.65M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $6.10M 10-K · filed 2025-03-06 | |||
| 2019-12-31 | $100.00K 10-K · filed 2020-03-12 | |||
| 2018-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $49.00K derived: sum of 2 quarters · filed 2020-03-12 | $71.00K derived: sum of 3 quarters · filed 2020-03-12 | $80.00K 10-K · filed 2020-03-12 |
| 2018-09-30 | $24.00K 10-Q · filed 2018-11-13 | $46.00K derived: sum of 2 quarters · filed 2018-11-13 | $55.00K 10-Q · filed 2018-11-13 | $57.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $31.00K 10-Q · filed 2018-08-09 | $33.00K derived: sum of 3 quarters · filed 2020-03-12 | $36.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $9.00K 10-Q · filed 2018-05-10 | $11.00K derived: sum of 2 quarters · filed 2020-03-12 | $14.00K derived: sum of 3 quarters · filed 2020-03-12 | $14.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $5.00K derived: sum of 2 quarters · filed 2020-03-12 | $5.00K derived: sum of 3 quarters · filed 2020-03-12 | $5.00K 10-K · filed 2020-03-12 |
| 2017-09-30 | $3.00K 10-Q · filed 2018-11-13 | $3.00K derived: sum of 2 quarters · filed 2018-11-13 | $3.00K 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $0.00 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |